Zobrazeno 1 - 10
of 287
pro vyhledávání: ''
Autor:
Robin Wijsman, Jonas Teuwen, Johan Bussink, B. Stam, M. Fernandes, René Monshouwer, Dominic A.X. Schinagl
Publikováno v:
Radiotherapy and Oncology, 165, pp. 52-59
Radiotherapy and Oncology, 165, 52-59. ELSEVIER IRELAND LTD
Radiotherapy and Oncology, 165, 52-59
Radiotherapy and Oncology, 165, 52-59. ELSEVIER IRELAND LTD
Radiotherapy and Oncology, 165, 52-59
Background and purpose: Large radiotherapy (RT) planning imaging datasets with consistently contoured cardiovascular structures are essential for robust cardiac radiotoxicity research in thoracic cancers. This study aims to develop and validate a hig
Publikováno v:
Radiotherapy and Oncology. 165:103-118
Backgrounds Concurrent chemo-radiotherapy in patients with locally advanced cervical cancer has significant hematologic toxicities (HT), leading to treatment disruption and affecting patient prognosis. We performed the meta-analysis to assess the cli
Autor:
Anouk Corbeau, Stephanie M. de Boer, Nanda Horeweg, Sander C. Kuipers, Remi A. Nout, Jeremy Godart, Mischa S. Hoogeman
Publikováno v:
Radiotherapy and Oncology, 164, 128-137. ELSEVIER IRELAND LTD
Patients with locally advanced cervical cancer (LACC) treated with chemoradiation often experience hematologic toxicity (HT), as chemoradiation can induce bone marrow (BM) suppression. Studies on the relationship between BM dosimetric parameters and
Autor:
Willem J.A. Witlox, Si Yu Wang, N. Li, Harry J.M. Groen, Matthias Guckenberger, Harm van Tinteren, Manuela A. Joore, Dirk De Ruysscher, Benjamin Lacas, Mary W. Redman, Cécile Le Péchoux, Alexander Sun, Chen Hu, Bram Ramaekers, Vincent van der Noort
Publikováno v:
Radiotherapy and Oncology, 164, 163-166. Elsevier Ireland Ltd
Radiotherapy and Oncology, 164, 163-166. ELSEVIER IRELAND LTD
Radiotherapy and Oncology, 164, 163-166. ELSEVIER IRELAND LTD
We assessed the impact of different PCI fractionation schedules (30 Gy in 10 versus 15 fractions) on brain metastases-free survival (BMFS) and toxicity in stage III NSCLC. Our results suggest that 30 Gy in 10 fractions is associated with increased to
Autor:
Linlin Wang, Pingfu Fu, Siming Gao, Jinming Yu, Weili Wang, J.Y. Jin, Feng-Ming Spring Kong, Mitchell Machtay, Yishan Yu
Publikováno v:
Radiotherapy and Oncology. 162:26-33
Background Effective dose to immune cell (EDIC), an estimated radiation dose to the circulating lymphocytes, is of significance for overall survival (OS) in non-small cell lung cancer. This study aimed to validate the EDIC’s OS effect on limited-st
Autor:
Tomas Janssen, Marcel C.J. Jonker, Corrie A.M. Marijnen, Rob Kessels, Charlotte L. Zuur, Arash Navran, Jan-Jakob Sonke, Jan de Boer, Olga Hamming-Vrieze, Abrahim Al-Mamgani
Publikováno v:
Radiotherapy and Oncology, 162, 170-177. ELSEVIER IRELAND LTD
Background and purpose: We aim to retrospectively investigate whether reducing GTV to high-risk CTV margin will significantly reduce acute and late toxicity without jeopardizing outcome in head-and neck squamous cell carcinoma (HNSCC) treated with de
Autor:
Mehmet Altan, Nathan Comeaux, Joe Y. Chang, Dawei Chen, Chad Tang, Adi Diab, Percy Lee, George R. Blumenschein, Maria E. Cabanillas, Mylene T. Truong, Renata Ferrarotto, Quynh-Nhu Nguyen, Baohua Sun, Saumil Gandhi, Brett W. Carter, Maria Angelica Cortez, Roshal R. Patel, David S. Hong, Vivek Verma, Kewen He, Stephen G. Chun, Shalin J. Shah, James W. Welsh, John V. Heymach, Jeremy J. Erasmus, Frank V. Fossella, Ying Yuan, Michael A. Davies, Edwin R. Parra, Hampartsoum B. Barsoumian, Duygu Sezen, Isabella C. Glitza, Matthew S. Ning
Publikováno v:
Radiotherapy and Oncology. 162:60-67
To report early findings from a phase II trial of high-dose radiotherapy (HD-RT) with or without low-dose RT (LD-RT) for metastatic cancer.Eligible patients had metastatic disease that progressed on immunotherapy within 6 months. Patients were given
Autor:
Erik W Korevaar, Roel J H M Steenbakkers, Arjen van der Schaaf, Johannes A. Langendijk, Stefan Both, Hans Paul van der Laan, Lisa Van den Bosch
Publikováno v:
Radiotherapy and Oncology, 162, 85-90. ELSEVIER IRELAND LTD
PURPOSE: To evaluate the feasibility of semi-automatic Quality of Life (QOL)-weighted normal tissue complication probability (NTCP)-guided VMAT treatment plan optimisation in head and neck cancer (HNC) and compare predicted QOL to that obtained with
Autor:
Patrick Cheung, Gerard Morton, Andrea Deabreu, Melanie Davidson, Andrew Loblaw, Ananth Ravi, Danny Vesprini, Stanley K. Liu, Hima Bindu Musunuru, Joelle Helou, Ling Ho, William Chu, Liying Zhang, Hans Chung
Publikováno v:
Radiotherapy and Oncology. 161:40-46
The ASCO/CCO guidelines recommend brachytherapy (BT) boost for eligible intermediate- (IR) or high-risk (HR) prostate cancer (PCa) patients. We present efficacy, toxicity and quality-of-life (QoL) outcomes in patients treated on a prospective protoco
Autor:
Georgia Miebach, Judit Boda-Heggemann, Szücs Marcella, Susanne Stera, Daniel Buergy, Michael Ehmann, A Giordano Frank, David Krug, Stefan Wurster, Oliver Blanck, Frank Lohr, Claus Rödel, Jens Fleckenstein, Constantin Dreher
Publikováno v:
Radiotherapy and Oncology. 158:230-236
Local treatment of metastases in combination with systemic therapy can prolong survival of oligo-metastasized patients. To fully exploit this potential, safe and effective treatments are needed to ensure long-term metastases control. Stereotactic bod